Provided is the use of quinolone derivative compounds of general formula I, where the variables are as defined in the specification, for the treatment of cancer. A preferred compound for use is N-(4-{ [6,7-bis(methyloxy)quinolin-4-yl} oxy} phenyl)-N’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide. A preferred cancer to be treated is renal cell carcinoma metastasised to bone.